Open Access<p>Carvedilol Alters Circulating MiR-1 and MiR-214 in Heart Failure</p>
Author(s) -
Elham Shirazi-Tehrani,
Negar Firouzabadi,
Gholamhossein Tamaddon,
Ehsan Bahramali,
Asma Vafadar
Publication year - 2020
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s263740
Subject(s) - carvedilol , medicine , heart failure , microrna , muscle hypertrophy , downregulation and upregulation , cardiac hypertrophy , ejection fraction , fibrosis , pathophysiology , cardiology , pharmacology , endocrinology , gene , biology , biochemistry
MicroRNAs (miRNAs) are recognized as major contributors in various cardiovascular diseases, such as heart failure (HF). These small noncoding RNAs that posttranscriptionally control target genes are involved in regulating different pathophysiological processes including cardiac proliferation, ifferentiation, hypertrophy, and fibrosis. Although carvedilol, a β-adrenergic blocker, and a drug of choice in HF produce cytoprotective actions against cardiomyocyte hypertrophy, the mechanisms are poorly understood. Here we proposed that the expression of hypertrophic-specific miRNAs (miR-1, miR-133, miR-208, and miR-214) might be linked to beneficial effects of carvedilol.